Development of anti-cancer cross-talk therapy using antibody and cell therapy

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670467
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Hematology
• Research Institution: Ehime University
• Principal Investigator: Yasukawa M 愛媛大学, 医学(系)研究科(研究院), 教授 (60127917)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: がん免疫療法 / 細胞傷害性T細胞 / ADCC活性 / キメラ遺伝子 / CD16

Outline of Final Research Achievements

The antibody therapy against malignancies depends on antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC is mediated by NK cells expressing CD16 on their cell surface; however, T cells cannot exert any ADCC activity, since they are negative for CD16 expression. In this study, we attempted to produce CD16-CD3z chimeric gene and to transduce it into activated CD8-positive T cells. CD16-CD3z T cells showed high ADCC activity in the presence of antibody in vitro. In addition, it was shown that the combination therapy of CD16-CD3z T cells and antibody against the cell surface molecule of malignant cells exerted anti-tumor activity in human tumor-transplanted immune-deficient mice.

Free Research Field

内科学、血液学、免疫学、感染症学